PROCEPT BioRobotics Corporation (PRCT): A Bull Case Theory

We came crossed a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we volition summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation's share was trading astatine $29.21 as of February 9th.

Master Video/Shutterstock.com

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses connected processing transformative solutions successful urology successful the United States and internationally. PRCT is positioning itself arsenic a imaginable caller golden modular successful the attraction of benign prostatic hyperplasia (BPH) done its automated robotic surgical system, AquaBeam. Today, the immense bulk of the tens of millions of men seeking attraction for BPH trust connected pharmaceuticals that are often imperfect, portion country represents lone a tiny fraction of the attraction landscape.

PRCT’s strategy is straightforward but ambitious: instrumentality stock from cause therapy by expanding the surgical marketplace with a differentiated, technology-driven solution. Since its 2021 IPO, gross has surged, with 2025 income expected to beryllium astir 9.5 times higher, reflecting accelerated adoption. However, contempt growth fueled by robotics and AI enthusiasm, the banal has reversed sharply successful 2025 arsenic investors grapple with cardinal uncertainties astir profitability, moderating growth, full addressable marketplace size, and the timing of breakeven—especially aft a caller CEO signaled increased near-term investment.

Leadership is cardinal to the thesis. Larry Wood, formerly of Edwards Lifesciences wherever helium helped standard TAVR into a multi-billion-dollar modular of care, present leads PRCT aft antecedently serving connected its board. His upcoming capitalist time is expected to outline multi-year gross and profitability targets, alongside strategical updates that could reset expectations.

The accidental hinges connected differentiated technology, credible execution, and patience amid uncertainty, with important optionality if PRCT successfully expands into adjacent markets. While the institution remains unprofitable and is valued connected EV/sales, its projected 2026 growth—roughly treble Intuitive Surgical and triple Boston Scientific—suggests meaningful upside if execution materializes, with acquisition imaginable besides a realistic outcome.

Previously, we covered a bullish thesis on Intuitive Surgical, Inc. (ISRG) by Kontra Investment Xchange successful December 2024, which highlighted the company’s enactment successful robotic surgery, expanding installed base, beardown process growth, AI integration, and agelong runway for planetary adoption. ISRG's banal terms has depreciated by astir 9.07% since our coverage. Crashkolnikov shares a akin thesis but emphasizes connected PROCEPT BioRobotics’ niche BPH absorption and earlier-stage maturation trajectory.